#aXichem #aXivite #CrossFit

aXichem's New Study Validates aXivite Performance

In a significant advancement for sports nutrition, aXichem AB announced the publication of its latest clinical trial in the esteemed Journal of the International Society of Sports Nutrition. The study titled Acute phenylcapsaicin supplementation improves exercise performance in CrossFit® trained adults underscores the measurable benefits of aXivite®, a supplement hailed for enhancing high-intensity performance.

Overview of the Study

Conducted by Dr. Pablo Jiménez Martínez and his team in Spain, the trial involved a randomized, triple-blind, placebo-controlled crossover method with 50 trained CrossFit athletes (25 males and 25 females). This meticulous approach ensured robust data collection, confirming the solid efficacy of aXivite®. Notably, participants received a single 2.5 mg dose, leading to remarkable enhancements in various performance metrics.

Key Findings

1. Superior Mechanical Output: The athletes who were supplemented with aXivite® displayed enhanced mechanical performance, achieving higher loads and repetitions during the deep squat tests at 70% of their one-rep max (1RM).
2. Extended Endurance: aXivite® allowed participants to sustain their weightlifting capabilities throughout intensive workout rounds, particularly when fatigue levels were at their peak.
3. Accelerated Recovery: The data revealed a statistically significant drop in Delayed-Onset Muscle Soreness (DOMS) at both 24 and 48 hours post-exercise. This reduction indicates how aXivite® facilitates faster recovery, allowing athletes to resume peak performance more swiftly.

Impact on the High-Intensity Performance Market

This recent publication marks a pivotal moment for aXichem and its flagship product, aXivite®. As Lucas Altepost, the VP of Sales and Marketing at aXichem, states,